26 Jan 2017 --- Johnson & Johnson have announced that it will acquire the European biotech giant, Actelion Ltd, a company responsible for the development of innovative products for pulmonary arterial hypertension (PAH). The two companies have entered a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer to acquire all of the outstanding shares of Actelion for $280 per share.
